Multiple Myeloma Management 对比 SurvivorNet 的使用情况和统计数据
Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.
- Apple 应用商店
- 免费
- 医疗
商店排名
- -
We believe far too many people still struggle to find information about treatments that can save their lives. SurvivorNet is closing this gap by creating a deep, video-based educational resource for patients featuring top physicians and researchers around the country. To create patient-focused educational content, the company is working with physicians at leading NCCN-designated cancer centers such as The National Cancer Institute, Dana-Farber, Memorial Sloan Kettering, Stanford, NYU, and M.D. Anderson.
- Apple 应用商店
- 免费
- 健康与健身
商店排名
- -
Multiple Myeloma Management VS. 
SurvivorNet十二月 19, 2024